DENTSPLY SIRONA (NASDAQ:XRAY) Director Gregory Lucier Buys 22,445 Shares

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier acquired 22,445 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was purchased at an average price of $14.03 per share, for a total transaction of $314,903.35. Following the acquisition, the director directly owned 50,000 shares of the company’s stock, valued at $701,500. The trade was a 81.46% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $13.30 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The stock has a market capitalization of $2.66 billion, a PE ratio of -4.43, a price-to-earnings-growth ratio of 1.68 and a beta of 0.97. DENTSPLY SIRONA Inc. has a 12-month low of $9.85 and a 12-month high of $17.18. The company has a 50 day moving average price of $12.52 and a two-hundred day moving average price of $12.47.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. During the same quarter last year, the company earned $0.26 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 4.8%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -21.33%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA in the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. raised its stake in DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. Empowered Funds LLC boosted its holdings in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares during the period. Finally, Focus Partners Wealth grew its position in DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after purchasing an additional 9,355 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier significantly increased his stake in Dentsply Sirona, purchasing 27,555 shares on March 2 at ~$14.24 and 22,445 shares on March 3 at ~$14.03 (bringing his reported holdings to ~50,000 shares). Large insider purchases are often viewed as a bullish signal of management confidence. SEC Form 4
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a bullish analyst action that implies meaningful upside from current levels and can support buying interest. Barrington Research PT Raise
• Neutral Sentiment: Mizuho raised its price target to $16 but kept a “neutral” rating — a PT lift that helps sentiment but the unchanged rating tempers the positive impact. Mizuho PT Update TickerReport
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a scheduled investor event that provides an opportunity for management to update guidance and interact with analysts (near-term catalyst if new commentary or data are released). Conference Notice
• Neutral Sentiment: Analyst coverage/targets: Smaller media posts also reported price-target bumps (AmericanBankingNews noted PTs raised to $13 and $14). These incremental upgrades help sentiment but are mixed in magnitude. PT to $13 PT to $14
• Neutral Sentiment: Fundamental note: A Zacks piece flagged international revenue trends as an area to watch; investors assessing XRAY should consider geographic growth dynamics versus company guidance/analyst models. Zacks Analysis
• Neutral Sentiment: Short-interest data appears anomalous (reports show zero shares / NaN changes), suggesting a reporting error rather than a genuine short-squeeze or relief — treat the short-interest updates cautiously. (No reliable link; data appears inconsistent in the filings.)

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on XRAY shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Barclays assumed coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 target price for the company. Robert W. Baird lifted their price target on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, Mizuho upped their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $14.42.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.